<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911435697</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911435697</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival Lesions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zoroquiain</surname><given-names>Pablo</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911435697">1</xref>
<xref ref-type="aff" rid="aff2-1066896911435697">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fernandes</surname><given-names>Bruno F.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1066896911435697">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>González</surname><given-names>Sergio</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1066896911435697">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Novais</surname><given-names>Gustavo N.</given-names></name>
<degrees>MD, FICO</degrees>
<xref ref-type="aff" rid="aff1-1066896911435697">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schalper</surname><given-names>Kurt A.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-1066896911435697">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Burnier</surname><given-names>Miguel N.</given-names><suffix>Jr.</suffix></name>
<degrees>MD, PhD, FRCSC</degrees>
<xref ref-type="aff" rid="aff1-1066896911435697">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911435697"><label>1</label>The Henry C. Witelson Ocular Pathology Laboratory, Montreal, Canada</aff>
<aff id="aff2-1066896911435697"><label>2</label>Pontificia Universidad Católica de Chile, Santiago, Chile</aff>
<author-notes>
<corresp id="corresp1-1066896911435697">Pablo Zoroquian, Department of Anatomic Pathology, Universidad Cátolica de Chile School of Medicine, Lira 85 4to Piso, Santiago de Chile, Region Metropolitana 8330074, Chile Email: <email>zoroquiain@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>240</fpage>
<lpage>245</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Acquired conjunctival melanocytic lesions include nevi, primary acquired melanoses (PAMs), and melanomas. Conjunctival melanoma is a malignant melanocytic neoplasm with a high metastasis and mortality rate. Usually, the diagnosis can be achieved only with routine microscopic analysis, but in some cases, the samples are small or have artifacts. In these cases, complementary studies will be helpful, but currently, there are no well-understood or studied complementary methods. <italic>Objective</italic>. To analyze the immunohistochemical expression of p16 in conjunctival melanocytic lesions and to assess its potential for differentiating between benign and malignant melanocytic lesions. <italic>Methods</italic>. Immunohistochemical study against p16ink4a (p16) was performed on paraffin-embedded sections on 45 melanocytic lesions (9 melanomas, 19 nevi, and 2 PAMs with atypia and 15 without atypia). Expression was scored according to the German immunoreactive score (IRS). <italic>Results</italic>. Expression of p16 IRS differed between nevi, PAMs, and melanomas. The mean IRS for melanomas was 3.3 ± 1.8 and was lower than those for nevi (7.63 ± 3.24; <italic>P</italic> &lt; .05), PAM with atypia (12 ± 0; <italic>P</italic> &lt; .05), and PAM without atypia (11 ± 1.69; <italic>P</italic> &lt; .05). Lesions with infiltration depths lower than 2 mm showed higher levels of p16. There were no differences between favorable and unfavorable locations. <italic>Conclusion</italic>. p16 Expression in conjunctival melanocytic lesions showed an expression similar to that in skin and seems to be a good marker to differentiate nevi and PAMs from melanomas. However, additional studies of larger series and follow-up are needed to confirm these findings.</p>
</abstract>
<kwd-group>
<kwd>conjunctival melanoma</kwd>
<kwd>conjunctival nevus</kwd>
<kwd>conjunctival tumor</kwd>
<kwd>p16ink4a</kwd>
<kwd>primary acquired melanosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896911435697" sec-type="intro">
<title>Introduction</title>
<p>The group of melanocytic lesions of the conjunctiva include a spectrum of benign lesions such as junctional, compound, and subepithelial nevi; malignant precursors such as primary acquired melanosis (PAM) with or without atypia; and conjunctival malignant melanoma. In spite of the fact that malignant melanoma of the conjunctiva is very rare, representing only 2% of ocular malignancies, it is of paramount importance to differentiate melanoma from other melanocytic lesions with lower malignant potential because conjunctival melanoma is associated with an adverse prognosis, with an 8-year mortality rate of 13% in the US population<sup><xref ref-type="bibr" rid="bibr1-1066896911435697">1</xref></sup> to a 10-year mortality rate of 30% in Sweden.<sup><xref ref-type="bibr" rid="bibr2-1066896911435697">2</xref></sup> Metastases are found in up to 65% of cases at 10 years.<sup><xref ref-type="bibr" rid="bibr3-1066896911435697">3</xref></sup> Usually, the diagnosis can be achieved only with conventional microscopic analysis of biopsies, and in many cases, complementary methods are required, with immunohistochemistry being the most commonly used one. However, bona fide determination of the benign or malignant nature of conjunctival melanocytic lesions in biopsy samples with the available tools is not always straightforward, especially in small incisional biopsies. Application of additional molecular markers and techniques could aid in this task.</p>
<p>Currently, the group of significant risk factors for recurrences of melanocytic lesions in the conjunctiva include irregular pigmentation, incomplete surgical excision, deeply invading tumors, epithelioid phenotype, and cTNM staging.<sup><xref ref-type="bibr" rid="bibr1-1066896911435697">1</xref>,<xref ref-type="bibr" rid="bibr4-1066896911435697">4</xref></sup> Risk factors associated with higher mortality include location in the palpebral conjunctiva, caruncle, plica, or fornices; tumor infiltration deeper than the substantia propria; incomplete surgical excision; and nodular or mixed (nodular and superficial) growth patterns.<sup><xref ref-type="bibr" rid="bibr5-1066896911435697">5</xref></sup> Because incisional biopsies do not always allow the assessment of the above described risk variables, excisional biopsies are recommended whenever possible. Markers for complementary assessment of the true biological nature of conjunctival melanocytic lesions might also help in avoiding overtreatment, cosmetic and functional drawbacks, and associated costs of unnecessary procedures. In addition, the aggressive clinical behavior of melanomas and the multimodal type of treatment for melanomas emphasize the need to identify and validate more accurate prognostic markers, refine risk stratification, and provide individual patients a more accurate estimate of their expected clinical course.<sup><xref ref-type="bibr" rid="bibr6-1066896911435697">6</xref></sup></p>
<p>One well-characterized genetic risk factor in skin melanoma is <italic>CDKN2A</italic> gene mutation. <italic>CDKN2A</italic> encodes p16ink4a (p16) protein.<sup><xref ref-type="bibr" rid="bibr7-1066896911435697">7</xref>,<xref ref-type="bibr" rid="bibr8-1066896911435697">8</xref></sup> <italic>CDKN2A</italic> germline mutations were found in up to 40% of individuals from 3 different families affected with well-documented familial melanomas.<sup><xref ref-type="bibr" rid="bibr9-1066896911435697">9</xref></sup> In addition, <italic>CDKN2A</italic> loss is believed to play a role in melanoma genesis through dysregulation of the cell cycle.<sup><xref ref-type="bibr" rid="bibr10-1066896911435697">10</xref></sup> p16 regulates the cell cycle through binding and deactivation of the cyclin-dependent kinase 4/6 complex (CDK4/6) bound to cyclin D.<sup><xref ref-type="bibr" rid="bibr11-1066896911435697">11</xref></sup> Thus, reduction or lack of p16 protein through mutation or gene deletion releases the CDK4/6–cyclin D complex inhibition at the transition from the G1 to the S phase. Cells carrying p16-inactivating mutations can replicate faster because mitotic activity increases, which is considered to be a major event in melanoma genesis.<sup><xref ref-type="bibr" rid="bibr12-1066896911435697">12</xref><xref ref-type="bibr" rid="bibr13-1066896911435697"/>-<xref ref-type="bibr" rid="bibr14-1066896911435697">14</xref></sup> In this regard, it has been reported that skin melanomas, but not benign melanocytic lesions, show reduced nuclear p16 expression.<sup><xref ref-type="bibr" rid="bibr14-1066896911435697">14</xref></sup> Immunohistochemical detection of p16 has also been proposed to be useful in differentiating nodal nevi from nodal metastatic melanomas.<sup><xref ref-type="bibr" rid="bibr15-1066896911435697">15</xref></sup></p>
<p>The aim of this present study was to analyze the immunohistochemical expression of p16 in conjunctival melanocytic lesions and to assess its potential for differentiating benign and atypical melanocytic lesions from melanomas.</p>
</sec>
<sec id="section2-1066896911435697" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1066896911435697">
<title>Samples and Morphological Review</title>
<p>Material from all the samples with the pathological diagnosis of conjunctival melanoma, PAM with or without atypia, and nevi during the 1993-2009 period were collected and included in the study. Hematoxylin eosin–stained slides were reexamined and classified by the investigators. Lesions were classified as PAM, PAM with atypia, conjunctival nevus, and conjunctival melanoma according to the Armed Forces Institute of Pathology classification system.<sup><xref ref-type="bibr" rid="bibr16-1066896911435697">16</xref></sup> A total of 45 cases with clinicopathological data retrieved from the archives of the Henry C. Witelson Ocular Pathology Laboratory, McGill University (Montreal, Quebec, Canada) were included in the study; 19 were common nevi; 17 were PAMs, 2 with atypia and 15 without atypia; and 9 were conjunctival melanomas. Our case set showed a slight female predominance, with 19 male (42%) and 26 female (58%) patients, with an average age of 51.6 ± 16 years.</p>
</sec>
<sec id="section4-1066896911435697">
<title>Immunohistochemistry</title>
<p>Automated immunohistochemistry was performed using a benchmark machine according to the manufacturer’s recommended protocol (Ventana Medical Systems, Inc, AZ). The fully automated processing of bar code–labeled slides included baking of the slides, solvent-free deparaffinization, and CC1 (Tris–EDTA buffer [pH 8.0])-based antigen retrieval. Slides were incubated with a monoclonal antihuman p16 antibody (Abcam, Cambridge, UK) at a dilution of 1:2000 for 30 minutes at 37°C followed by application of biotinylated secondary antibody for 8 minutes at 37°C; then, an avidin–streptavidin enzyme conjugate complex was added. Finally, Fast Red was used as a chromogenic substrate, and slides were counterstained with hematoxylin. Human brain tissue slices were used as positive controls, and negative controls were obtained by omitting the primary antibody.</p>
<p>Immunohistochemical p16 expression was assessed by assigning each case a score based on the percentage of nuclear-stained cells and their relative staining intensity, as previously described.<sup><xref ref-type="bibr" rid="bibr17-1066896911435697">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911435697">18</xref></sup> All cases were evaluated independently by 2 pathologists, and the results of each case included measurements of 10 random fields in each slide at 400× magnification using an Olympus BX51 upright microscope (Olympus, Tokyo, Japan). For determination of the percentage of immunoreactive cells, absence of staining was scored as 0; 1% to 10% of positive cells were scored as 1, 11% to 50% as 2, 51% to 80% as 3, and 81% to 100% as 4. Staining intensity was rated on a semiquantitative scale using the nuclei of basal keratinocytes as internal reference and scored from 0 to 3, with 0 = <italic>negative</italic>, 1 = <italic>weak</italic>, 2 = <italic>moderate</italic>, and 3 = <italic>strong nuclear staining</italic>. Data were then converted to the numeric German Immunoreactive Score (IRS) by multiplying the amount and staining intensity scores,<sup><xref ref-type="bibr" rid="bibr17-1066896911435697">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911435697">18</xref></sup> resulting in a possible range of 0 to 12. Discrepancies were reevaluated, and a consensus was reached in all cases. All data accumulation was in accordance with Canada and Province of Quebec legislation and the tenets of the Declaration of Helsinki.</p>
</sec>
<sec id="section5-1066896911435697">
<title>Data Management and Statistical Analysis</title>
<p>Data are presented as means ± standard errors (SEM), and n represents the number of cases. Means for each group were compared using 1-way ANOVA and Student’s <italic>t</italic> test. The presence of positive or negative correlation between variables was evaluated using the linear regression analysis and Pearson’s correlation test. Differences were considered significant at <italic>P</italic> &lt; .05. Statistics were performed using the Microsoft Excel and the GraphPad Prism 5.0 software.</p>
</sec>
</sec>
<sec id="section6-1066896911435697" sec-type="results">
<title>Results</title>
<p>All cases with PAM without atypia showed a clear nuclear staining pattern on the epithelial basal cells as in the melanocytes of the lesion; only in 3 lesions were the melanocytes clearly discernible, and most of them only showed a hyperpigmentation of the basal epithelial cells without evident melanocytic hyperplasia. This “normal” basal epithelial cell staining served as an internal positive control for p16, as a comparison to contrast the different staining intensities and to validate the numerical score of the IRS.</p>
<p>Similar to PAMs without atypia (<xref ref-type="fig" rid="fig1-1066896911435697">Figure 1</xref>), p16 showed a clear nuclear staining pattern in cases of PAM with atypia and nevi. In addition, cases with PAM with or without atypia and nevi showed comparable IRS scores (<italic>P</italic> &gt; .05). Besides its role as a tumor suppressor, p16 has also been associated with cellular senescence in nontransformed cells and tissues.<sup><xref ref-type="bibr" rid="bibr19-1066896911435697">19</xref></sup> It is interesting to note that there was no relationship between the IRS score and the age of the patients (<italic>r</italic><sup><xref ref-type="bibr" rid="bibr2-1066896911435697">2</xref></sup> = 0.08, <italic>P</italic> &gt; .05), ruling out any possible influence of or bias in the p16 immunoreactivity assessment resulting from age differences of the included cases.</p>
<fig id="fig1-1066896911435697" position="float">
<label>Figure 1.</label>
<caption><p>A. Conjunctival melanoma with p16 IRS of 2. B. Conjunctival melanoma with p16 IRS of 4. p16-negative mitosis (inset). C. PAM with atypia with p16IRS of 10. D. Subepithelial nevus with p16 IRS of 12. E. PAM without atypia. Graph shows a p16 IRS of the different melanocytic lesions using ANOVA (<italic>P</italic> &lt; .0001)</p>
<p>Abbreviations: IRS, immunoreactive score; ns, nonsignificant; PAM, primary acquired melanosis; w/a, with atypia; wo/a, without atypia.</p>
<p>*Significant. All figures are with a magnification of 400.</p></caption>
<graphic xlink:href="10.1177_1066896911435697-fig1.tif"/>
</fig>
<p>As shown in <xref ref-type="fig" rid="fig1-1066896911435697">Figure 1</xref>, cases with melanoma showed lower p16 levels than all the other studied melanocytic lesions of the conjunctiva. The IRS score for melanomas averaged 3.3 ± 1.8 and was significantly lower than lesions lacking malignant potential, including PAM without atypia (11 ± 1.69, <italic>P</italic> &lt; .05) and nevi (7.63 ± 3.24, <italic>P</italic> &lt; .05; <xref ref-type="fig" rid="fig2-1066896911435697">Figure 2</xref>). The IRS score of melanomas was also lower than that of PAMs with atypia (12 ± 0, <italic>P</italic> &lt; .05; <xref ref-type="fig" rid="fig2-1066896911435697">Figure 2</xref>), suggesting acquired p16 loss during the PAM with atypia-melanoma progression. It was interesting to note that PAMs with atypia showed higher p16 levels than common nevi (<italic>P</italic> &lt; .05; <xref ref-type="fig" rid="fig2-1066896911435697">Figure 2</xref>), challenging the involvement of common nevi in the p16-mediated melanoma progression model.</p>
<fig id="fig2-1066896911435697" position="float">
<label>Figure 2.</label>
<caption><p>p16 IRS in melanomas according to the depth of invasion (A) and according to a favorable or unfavorable localization (B)</p>
<p>Abbreviations: IRS, immunoreactive score.</p>
<p>*Significant.</p></caption>
<graphic xlink:href="10.1177_1066896911435697-fig2.tif"/>
</fig>
<p>The depth of invasion is recognized as the most relevant prognostic indicator in melanocytic lesions from diverse body sites (eg, Clark’s levels and Breslow depth). When the p16 level was evaluated according to the depth of invasion, superficial melanomas with vertical infiltration below 2 mm showed higher p16 levels than those achieving deeper infiltration (<italic>P</italic> &lt; .01; <xref ref-type="fig" rid="fig2-1066896911435697">Figure 2A</xref>). No differences in the p16 levels were detected according to favorable or unfavorable eye location of the lesion (<italic>P</italic> &gt; .05; <xref ref-type="fig" rid="fig2-1066896911435697">Figure 2B</xref>).</p>
</sec>
<sec id="section7-1066896911435697" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we evaluated whether the immunohistochemical expression of p16 may help differentiate benign from malignant conjunctival melanocytic lesions. There are only a few published studies showing differences in the staining pattern of the different melanocytic lesions.<sup><xref ref-type="bibr" rid="bibr20-1066896911435697">20</xref><xref ref-type="bibr" rid="bibr21-1066896911435697"/>-<xref ref-type="bibr" rid="bibr22-1066896911435697">22</xref></sup> Here, we showed that p16 levels differed in terms of nevi, PAM with or without atypia, and conjunctival melanomas. It is interesting to note that melanomas showed a comparable p16 staining pattern (nuclear) but lower levels than benign melanocytic lesions and PAMs with atypia (<italic>P</italic> &lt; .001). The latter findings might be useful as a complementary method to help in differentiating benign from malignant melanocytic lesions of the conjunctiva. According to our findings, when a melanocytic lesion that infiltrates the <italic>subepithelial stroma</italic> has a p16 IRS ≤ 4, it is most likely a melanoma On the other hand, when this melanocytic lesion has a p16 IRS ≥ 7, it is most likely a nevus. A p16 IRS between 4 to 7 makes the diagnosis inconclusive by this method alone. In our series, 7 melanomas had a p16 IRS ≤ 4, 11 nevi had a p16 IRS ≥ 7, and only 10 lesions were indeterminate.</p>
<p>In our study, nevi showed a higher expression of p16 than melanomas, in accordance with previous reports of skin melanocytic lesions.<sup><xref ref-type="bibr" rid="bibr6-1066896911435697">6</xref>,<xref ref-type="bibr" rid="bibr14-1066896911435697">14</xref></sup> This could be diagnostically useful because there are some nevi that mimic melanomas, and in those cases, a p16 immunostaining could be used as an ancillary method.</p>
<p>PAMs with atypia also showed a higher p16 IRS than melanomas but no difference when compared with nevi. This result was unexpected because in the skin, melanoma in situ has a staining similar to infiltrating melanoma and lower than that for nevi. These findings favor the notion that melanoma in situ is different from PAM with atypia in several ways.<sup><xref ref-type="bibr" rid="bibr14-1066896911435697">14</xref>,<xref ref-type="bibr" rid="bibr23-1066896911435697">23</xref></sup> Because this study included only 2 cases of PAMs with atypia and both with equal p16 IRS values (decreasing statistical power), a larger study including more cases will be required to make definitive conclusions.</p>
<p>p16 Has been proposed as a prognostic marker in skin melanocytic lesions.<sup><xref ref-type="bibr" rid="bibr6-1066896911435697">6</xref>,<xref ref-type="bibr" rid="bibr24-1066896911435697">24</xref>,<xref ref-type="bibr" rid="bibr25-1066896911435697">25</xref></sup> The data presented in this manuscript suggest that p16 could also be a prognostic indicator in melanocytic conjunctival lesions. To confirm its usefulness as a prognostic tool, a larger sample of melanoma cases with follow-up history would be needed</p>
<p>Currently, only 8 studies using immunohistochemical or immunofluorescent markers were available to differentiate benign from malignant lesions of the conjunctiva. Only FISH (fluorescent in situ hybridization) panel and the immunohistochemical markers S100A1, Ki-67, and HMB-45 achieved positive results.<sup><xref ref-type="bibr" rid="bibr20-1066896911435697">20</xref><xref ref-type="bibr" rid="bibr21-1066896911435697"/>-<xref ref-type="bibr" rid="bibr22-1066896911435697">22</xref></sup> Several differences have been noted in the immunostaining with HMB-45 in different studies, with significant differences between nevi and melanomas noted in Jackobiec et al<sup><xref ref-type="bibr" rid="bibr22-1066896911435697">22</xref></sup> (<italic>P</italic> &lt; .001; n = 35) and Sharara et al<sup><xref ref-type="bibr" rid="bibr20-1066896911435697">20</xref></sup> (<italic>P</italic> &lt; .001; n = 75) but also negative results by Stehul et al26 (<italic>P</italic> &gt; .05; n = 63). In a recent study, Busam et al<sup><xref ref-type="bibr" rid="bibr27-1066896911435697">27</xref></sup> described the expression of signals by FISH at RREB1(6p25), MYB(6q23), CCND1 (11q13), and centromere 6, finding that all the 8 melanomas studied were positive, and the 4 nevi were negative. On the other hand, Keijser et al<sup><xref ref-type="bibr" rid="bibr21-1066896911435697">21</xref></sup> showed a higher expression of S100a1, which is a member of the calcium-binding protein family S100, in melanomas when compared with nevi (71.4% and 30.6%, respectively). PAM with and without atypia were grouped together and showed an intermediate staining (45%). The study by Iwamoto et al<sup><xref ref-type="bibr" rid="bibr28-1066896911435697">28</xref></sup> was more descriptive but focused on the expression of different markers in conjunctival melanomas only. To date, there is just 1 publication dealing with p16 expression in conjunctival melanocytic tumors.<sup><xref ref-type="bibr" rid="bibr29-1066896911435697">29</xref></sup> Even though there were no differences between nevi and melanomas, the study was centered on hormonal receptor expression and secondarily on other markers, and the authors used only 2 melanomas in the sample (<xref ref-type="table" rid="table1-1066896911435697">Table 1</xref>).</p>
<table-wrap id="table1-1066896911435697" position="float">
<label>Table 1.</label>
<caption><p>Immunohistochemical and FISH Studies Described in the Literature Dealing With Conjunctival Melanomas</p></caption>
<graphic alternate-form-of="table1-1066896911435697" xlink:href="10.1177_1066896911435697-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Author (year)</th>
<th align="center">Immunohistochemistry Used</th>
<th align="center">Number of Cases</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>McDonnell et al<sup><xref ref-type="bibr" rid="bibr30-1066896911435697">30</xref></sup></td>
<td>HMB-45</td>
<td>45</td>
<td>UK</td>
<td>Only abstract available</td>
</tr>
<tr>
<td>Steuhl et al<sup><xref ref-type="bibr" rid="bibr26-1066896911435697">26</xref></sup></td>
<td>S100</td>
<td>63</td>
<td>&gt;.05(NS)</td>
<td/>
</tr>
<tr>
<td/>
<td>HMB45</td>
<td>63</td>
<td>&gt;.05(NS)</td>
<td/>
</tr>
<tr>
<td>Sharara et al<sup><xref ref-type="bibr" rid="bibr20-1066896911435697">20</xref></sup></td>
<td>S100</td>
<td>92</td>
<td>&gt;.05 (NS)</td>
<td/>
</tr>
<tr>
<td/>
<td>HMB45</td>
<td>76</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td/>
<td>NCI/C3</td>
<td>76</td>
<td>&gt;.05</td>
<td/>
</tr>
<tr>
<td>Iwamoto et al<sup><xref ref-type="bibr" rid="bibr28-1066896911435697">28</xref></sup></td>
<td>S100</td>
<td>11</td>
<td>NA</td>
<td>Only melanomas</td>
</tr>
<tr>
<td/>
<td>Tyrosinase</td>
<td>11</td>
<td>NA</td>
<td>Only melanomas</td>
</tr>
<tr>
<td/>
<td>HMB 45-50</td>
<td>11</td>
<td>NA</td>
<td>Only melanomas</td>
</tr>
<tr>
<td/>
<td>Microphthalmia transcription factor</td>
<td>11</td>
<td>NA</td>
<td>Only melanomas</td>
</tr>
<tr>
<td/>
<td>P75 neurotrophin receptor</td>
<td>11</td>
<td>NA</td>
<td>Only melanomas</td>
</tr>
<tr>
<td>Keijser et al<sup><xref ref-type="bibr" rid="bibr21-1066896911435697">21</xref></sup></td>
<td>S100A1</td>
<td>46</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td>Pache et al<sup><xref ref-type="bibr" rid="bibr29-1066896911435697">29</xref></sup></td>
<td>E2</td>
<td>76</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn2-1066896911435697">a</xref></sup></td>
<td>Only 2 melanomas</td>
</tr>
<tr>
<td/>
<td>PG</td>
<td>76</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn2-1066896911435697">a</xref></sup></td>
<td>Only 2 melanomas</td>
</tr>
<tr>
<td/>
<td>p16</td>
<td>76</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn2-1066896911435697">a</xref></sup></td>
<td>Only 2 melanomas</td>
</tr>
<tr>
<td>Busam et al<sup><xref ref-type="bibr" rid="bibr27-1066896911435697">27</xref></sup></td>
<td>FISH (RREB1, MYB, CCND1)</td>
<td>10</td>
<td>NA</td>
<td>FISH positive only in melanomas</td>
</tr>
<tr>
<td>Jakobiec et al<sup><xref ref-type="bibr" rid="bibr22-1066896911435697">22</xref></sup></td>
<td>Ki-67</td>
<td>35</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td/>
<td>HMB-45</td>
<td>35</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td/>
<td>S-100</td>
<td>35</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn2-1066896911435697">a</xref></sup></td>
<td/>
</tr>
<tr>
<td/>
<td>MART-1</td>
<td>35</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn2-1066896911435697">a</xref></sup></td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911435697">
<p>Abbreviations: FISH, fluorescent in situ hybridization; UK, unknown; NS, nonsignificative; NA, not available.</p></fn>
<fn id="table-fn2-1066896911435697">
<label>a</label>
<p>Without <italic>P</italic> value available.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Superficial infiltrative malignant lesions (defined as having a depth &lt; 2 mm)<sup><xref ref-type="bibr" rid="bibr1-1066896911435697">1</xref></sup> showed a lower IRS than the deeper-invading lesions. This difference in IRS on superficial versus deep penetrating lesions has not been reported on the skin. In the skin, metastatic lesions have the tendency to show lower expression of p16 than the primary tumor.<sup><xref ref-type="bibr" rid="bibr15-1066896911435697">15</xref></sup> Also for cutaneous melanomas, lower expression of p16 is associated with worse prognosis.<sup><xref ref-type="bibr" rid="bibr31-1066896911435697">31</xref></sup> Given the fact that it is well known that the prognosis in skin melanoma is directly related to the depth of invasion (Breslow and Clark indexes), we could assume that it is possible to demonstrate that the deeper the lesion, the higher the p16 IRS would be; p16 expression could have a prognosis correlation, but new studies with a longer follow-up are required.</p>
<p>Location of the primary lesion is also a prognostic factor in conjunctival tumors.<sup><xref ref-type="bibr" rid="bibr1-1066896911435697">1</xref>,<xref ref-type="bibr" rid="bibr3-1066896911435697">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896911435697">5</xref></sup> Unfortunately, in our study, there were no differences between IRS regarding the favorable or unfavorable topography of the tumor. Only 2 unfavorable cases were found, and both were from the tarsal conjunctiva, suggesting that these results are only a result of the small series studied (<xref ref-type="fig" rid="fig2-1066896911435697">Figure 2</xref>).</p>
<p>In summary, we evaluated p16 IRSs, which have been previously used for melanocytic tumors in the skin. There are several studies that show molecular similarities between skin and conjunctival melanomas, such as chromosomal aberration<sup><xref ref-type="bibr" rid="bibr27-1066896911435697">27</xref></sup> and the presence of v-raf murine sarcoma viral oncogene homolog B1 (BRAF mutation).<sup><xref ref-type="bibr" rid="bibr23-1066896911435697">23</xref>,<xref ref-type="bibr" rid="bibr32-1066896911435697">32</xref></sup> p16 Seems to be a promising marker to differentiate conjunctival nevi and PAM with atypia from conjunctival melanoma. Additional studies on larger series with follow-up are needed to confirm these findings. An immunohistochemical marker would greatly help the pathologist to make such important distinctions in conjunctival biopsies, which are invariably small, and ultimately improve patient care by distinguishing those in need of a more aggressive therapy.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict"><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn>
<fn fn-type="financial-disclosure"><p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911435697">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shields</surname><given-names>CL</given-names></name>
<name><surname>Shields</surname><given-names>JA</given-names></name>
<name><surname>Gunduz</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients</article-title>. <source>Arch Ophthalmol</source>. <year>2000</year>;<volume>118</volume>:<fpage>1497</fpage>-<lpage>1507</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911435697">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seregard</surname><given-names>S</given-names></name>
<name><surname>Kock</surname><given-names>E</given-names></name>
</person-group>. <article-title>Conjunctival malignant melanoma in Sweden 1969-91</article-title>. <source>Acta Ophthalmol (Copenh)</source>. <year>1992</year>;<volume>70</volume>:<fpage>289</fpage>-<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911435697">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shields</surname><given-names>CL</given-names></name>
<name><surname>Demirci</surname><given-names>H</given-names></name>
<name><surname>Karatza</surname><given-names>E</given-names></name>
<name><surname>Shields</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors</article-title>. <source>Ophthalmology</source>. <year>2004</year>;<volume>111</volume>:<fpage>1747</fpage>-<lpage>1754</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911435697">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paridaens</surname><given-names>AD</given-names></name>
<name><surname>Minassian</surname><given-names>DC</given-names></name>
<name><surname>McCartney</surname><given-names>AC</given-names></name>
<name><surname>Hungerford</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases</article-title>. <source>Br J Ophthalmol</source>. <year>1994</year>;<volume>78</volume>:<fpage>252</fpage>-<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911435697">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anastassiou</surname><given-names>G</given-names></name>
<name><surname>Heiligenhaus</surname><given-names>A</given-names></name>
<name><surname>Bechrakis</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study</article-title>. <source>Br J Ophthalmol</source>. <year>2002</year>;<volume>86</volume>:<fpage>163</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911435697">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gogas</surname><given-names>H</given-names></name>
<name><surname>Eggermont</surname><given-names>AM</given-names></name>
<name><surname>Hauschild</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Biomarkers in melanoma</article-title>. <source>Ann Oncol</source>. <year>2009</year>;<volume>20</volume>(<issue>suppl 6</issue>):<fpage>8</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911435697">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soufir</surname><given-names>N</given-names></name>
<name><surname>Avril</surname><given-names>MF</given-names></name>
<name><surname>Chompret</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group</article-title>. <source>Hum Mol Genet</source>. <year>1998</year>;<volume>7</volume>:<fpage>209</fpage>-<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911435697">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castellano</surname><given-names>M</given-names></name>
<name><surname>Pollock</surname><given-names>PM</given-names></name>
<name><surname>Walters</surname><given-names>MK</given-names></name>
<etal/>
</person-group>. <article-title>CDKN2A/p16 is inactivated in most melanoma cell lines</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>:<fpage>4868</fpage>-<lpage>4875</lpage>.</citation>
</ref>
<ref id="bibr9-1066896911435697">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Snoo</surname><given-names>FA</given-names></name>
<name><surname>Bishop</surname><given-names>DT</given-names></name>
<name><surname>Bergman</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>:<fpage>7151</fpage>-<lpage>7157</lpage>.</citation>
</ref>
<ref id="bibr10-1066896911435697">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Sanki</surname><given-names>A</given-names></name>
<name><surname>Karim</surname><given-names>RZ</given-names></name>
<etal/>
</person-group>. <article-title>The role of cell cycle regulatory proteins in the pathogenesis of melanoma</article-title>. <source>Pathology</source>. <year>2006</year>;<volume>38</volume>:<fpage>287</fpage>-<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr11-1066896911435697">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ortega</surname><given-names>S</given-names></name>
<name><surname>Malumbres</surname><given-names>M</given-names></name>
<name><surname>Barbacid</surname><given-names>M</given-names></name>
</person-group>. <article-title>Cyclin D-dependent kinases, INK4 inhibitors and cancer</article-title>. <source>Biochim Biophys Acta</source>. <year>2002</year>;<volume>1602</volume>:<fpage>73</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr12-1066896911435697">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nobori</surname><given-names>T</given-names></name>
<name><surname>Miura</surname><given-names>K</given-names></name>
<name><surname>Wu</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. <article-title>Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers</article-title>. <source>Nature</source>. <year>1994</year>;<volume>368</volume>:<fpage>753</fpage>-<lpage>756</lpage>.</citation>
</ref>
<ref id="bibr13-1066896911435697">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pastorino</surname><given-names>L</given-names></name>
<name><surname>Bonelli</surname><given-names>L</given-names></name>
<name><surname>Ghiorzo</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma</article-title>. <source>Pigment Cell Melanoma Res</source>. <year>2008</year>;<volume>21</volume>:<fpage>700</fpage>-<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr14-1066896911435697">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karim</surname><given-names>RZ</given-names></name>
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Sanki</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors</article-title>. <source>Int J Surg Pathol</source>. <year>2009</year>;<volume>17</volume>:<fpage>361</fpage>-<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr15-1066896911435697">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mihic-Probst</surname><given-names>D</given-names></name>
<name><surname>Saremaslani</surname><given-names>P</given-names></name>
<name><surname>Komminoth</surname><given-names>P</given-names></name>
<name><surname>Heitz</surname><given-names>PU</given-names></name>
</person-group>. <article-title>Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus</article-title>. <source>Virchows Arch</source>. <year>2003</year>;<volume>443</volume>:<fpage>745</fpage>-<lpage>751</lpage>.</citation>
</ref>
<ref id="bibr16-1066896911435697">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Font</surname><given-names>R C</given-names></name>
<name><surname>Narsing</surname><given-names>R</given-names></name>
</person-group>, eds. <source>Tumors of the Eye and Ocular Adnexa</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>ARP Press</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr17-1066896911435697">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rush</surname><given-names>DS</given-names></name>
<name><surname>Tan</surname><given-names>J</given-names></name>
<name><surname>Baergen</surname><given-names>RN</given-names></name>
<name><surname>Soslow</surname><given-names>RA</given-names></name>
</person-group>. <article-title>h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma</article-title>. <source>Am J Surg Pathol</source>. <year>2001</year>;<volume>25</volume>:<fpage>253</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr18-1066896911435697">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remmele</surname><given-names>W</given-names></name>
<name><surname>Stegner</surname><given-names>HE</given-names></name>
</person-group>. <article-title>Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]</article-title>. <source>Pathologe</source>. <year>1987</year>;<volume>8</volume>:<fpage>138</fpage>-<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr19-1066896911435697">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romagosa</surname><given-names>C</given-names></name>
<name><surname>Simonetti</surname><given-names>S</given-names></name>
<name><surname>Lopez-Vicente</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors</article-title>. <source>Oncogene</source>. <year>2011</year>;<volume>30</volume>:<fpage>2087</fpage>-<lpage>2097</lpage>.</citation>
</ref>
<ref id="bibr20-1066896911435697">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharara</surname><given-names>NA</given-names></name>
<name><surname>Alexander</surname><given-names>RA</given-names></name>
<name><surname>Luthert</surname><given-names>PJ</given-names></name>
<name><surname>Hungerford</surname><given-names>JL</given-names></name>
<name><surname>Cree</surname><given-names>IA</given-names></name>
</person-group>. <article-title>Differential immunoreactivity of melanocytic lesions of the conjunctiva</article-title>. <source>Histopathology</source>. <year>2001</year>;<volume>39</volume>:<fpage>426</fpage>-<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr21-1066896911435697">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keijser</surname><given-names>S</given-names></name>
<name><surname>Missotten</surname><given-names>GS</given-names></name>
<name><surname>Bonfrer</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions</article-title>. <source>Br J Ophthalmol</source>. <year>2006</year>;<volume>90</volume>:<fpage>213</fpage>-<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr22-1066896911435697">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jakobiec</surname><given-names>FA</given-names></name>
<name><surname>Bhat</surname><given-names>P</given-names></name>
<name><surname>Colby</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Immunohistochemical studies of conjunctival nevi and melanomas</article-title>. <source>Arch Ophthalmol</source>. <year>2010</year>;<volume>128</volume>:<fpage>174</fpage>-<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr23-1066896911435697">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldenberg-Cohen</surname><given-names>N</given-names></name>
<name><surname>Cohen</surname><given-names>Y</given-names></name>
<name><surname>Rosenbaum</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>T1799A BRAF mutations in conjunctival melanocytic lesions</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2005</year>;<volume>46</volume>:<fpage>3027</fpage>-<lpage>3030</lpage>.</citation>
</ref>
<ref id="bibr24-1066896911435697">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gould Rothberg</surname><given-names>BE</given-names></name>
<name><surname>Bracken</surname><given-names>MB</given-names></name>
<name><surname>Rimm</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>:<fpage>452</fpage>-<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr25-1066896911435697">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gould Rothberg</surname><given-names>BE</given-names></name>
<name><surname>Berger</surname><given-names>AJ</given-names></name>
<name><surname>Molinaro</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. <article-title>Melanoma prognostic model using tissue microarrays and genetic algorithms</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>:<fpage>5772</fpage>-<lpage>5780</lpage>.</citation>
</ref>
<ref id="bibr26-1066896911435697">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steuhl</surname><given-names>KP</given-names></name>
<name><surname>Rohrbach</surname><given-names>JM</given-names></name>
<name><surname>Knorr</surname><given-names>M.</given-names></name>
</person-group> <article-title>Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva [in German]</article-title>. <source>Klin Monbl Augenheilkd</source>. <year>1991</year>;<volume>199</volume>:<fpage>187</fpage>-<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr27-1066896911435697">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Busam</surname><given-names>KJ</given-names></name>
<name><surname>Fang</surname><given-names>Y</given-names></name>
<name><surname>Jhanwar</surname><given-names>SC</given-names></name>
<etal/>
</person-group>. <article-title>Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization</article-title>. <source>J Cutan Pathol</source>. <year>2010</year>;<volume>37</volume>:<fpage>196</fpage>-<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr28-1066896911435697">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwamoto</surname><given-names>S</given-names></name>
<name><surname>Burrows</surname><given-names>RC</given-names></name>
<name><surname>Grossniklaus</surname><given-names>HE</given-names></name>
<etal/>
</person-group>. <article-title>Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas</article-title>. <source>Arch Ophthalmol</source>. <year>2002</year>;<volume>120</volume>:<fpage>1625</fpage>-<lpage>1629</lpage>.</citation>
</ref>
<ref id="bibr29-1066896911435697">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pache</surname><given-names>M</given-names></name>
<name><surname>Glatz-Krieger</surname><given-names>K</given-names></name>
<name><surname>Sauter</surname><given-names>G</given-names></name>
<name><surname>Meyer</surname><given-names>P</given-names></name>
</person-group>. <article-title>Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source>. <year>2006</year>;<volume>244</volume>:<fpage>113</fpage>-<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr30-1066896911435697">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonnell</surname><given-names>JM</given-names></name>
<name><surname>Sun</surname><given-names>YY</given-names></name>
<name><surname>Wagner</surname><given-names>D</given-names></name>
</person-group>. <article-title>HMB-45 immunohistochemical staining of conjunctival melanocytic lesions</article-title>. <source>Ophthalmology</source>. <year>1991</year>;<volume>98</volume>:<fpage>453</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr31-1066896911435697">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Straume</surname><given-names>O</given-names></name>
<name><surname>Sviland</surname><given-names>L</given-names></name>
<name><surname>Akslen</surname><given-names>LA</given-names></name>
</person-group>. <article-title>Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>;<volume>6</volume>:<fpage>1845</fpage>-<lpage>1853</lpage>.</citation>
</ref>
<ref id="bibr32-1066896911435697">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spendlove</surname><given-names>HE</given-names></name>
<name><surname>Damato</surname><given-names>BE</given-names></name>
<name><surname>Humphreys</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>BRAF mutations are detectable in conjunctival but not uveal melanomas</article-title>. <source>Melanoma Res</source>. <year>2004</year>;<volume>14</volume>:<fpage>449</fpage>-<lpage>452</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>